图卡替尼联合T-DM1治疗HER2阳性转移性乳腺癌的1b期临床试验
这项1b期开放标签多中心试验纳入57例既往接受过曲妥珠单抗和紫杉类治疗的HER2阳性转移性乳腺癌患者,评估图卡替尼联合T-DM1的最大耐受剂量、安全性和初步抗肿瘤活性。图卡替尼最大耐受剂量为300 mg每日两次,联合方案总体毒性可接受,在经多线治疗(含脑转移)患者中显示初步抗肿瘤活性。
要点
- 图卡替尼联合T-DM1的最大耐受剂量为图卡替尼300 mg每日两次。
- 350 mg每日两次时出现剂量限制性毒性反应。
- 联合方案在经多线治疗的HER2阳性转移性乳腺癌中显示初步抗肿瘤活性。
核心结论
- 图卡替尼联合T-DM1在经多线治疗的HER2阳性转移性乳腺癌患者中毒性可接受并显示初步抗肿瘤活性。
研究设计与样本
- 1b期开放标签多中心临床试验,2014年1月22日至2015年6月22日入组57例既往接受过曲妥珠单抗和紫杉类治疗的HER2阳性转移性乳腺癌患者。
主要发现
- 图卡替尼最大耐受剂量为300 mg每日两次,350 mg每日两次时出现剂量限制性毒性。
- 药代动力学分析显示图卡替尼与T-DM1无药物相互作用。
- 在最大耐受剂量治疗的50例患者中,任何原因的不良事件包括恶心36例(72%)、腹泻30例(60%)、乏力28例(56%)、鼻出血22例(44%)、头痛22例(44%)、呕吐21例(42%)、便秘21例(42%)和食欲下降20例(40%),大多数为1级或2级。
- 图卡替尼相关3级及以上毒性反应包括血小板减少7例(14%)和肝转氨酶升高6例(12%)。
临床怎么用
- 图卡替尼300 mg每日两次联合T-DM1可作为经曲妥珠单抗、帕妥珠单抗和T-DM1治疗后进展的HER2阳性转移性乳腺癌患者的潜在治疗选择。
局限性
- 本研究为1b期开放标签单臂试验,样本量57例,初步抗肿瘤活性需后续随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer. OBJECTIVE: To determine the maximum tolerated dosage of tucatinib in combination with T-DM1 in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. DESIGN, SETTING, AND PARTICIPANTS: In this phase 1b open-label, multicenter, clinical trial, 57 participants enrolled between January 22, 2014, and June 22, 2015, were 18 years of age or older with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Data were analyzed between January and March 2018. INTERVENTIONS: Tucatinib 300 mg or 350 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days. MAIN OUTCOMES AND MEASURES: Safety assessments, pharmacokinetics, and response were assessed using RECIST 1.1 every 2 cycles for 6 cycles, followed by every 3 cycles. RESULTS: Fifty-seven T-DM1-naive patients (median [IQR] 51 [44.0-63.0] years of age) who had undergone a median of 2 earlier HER2 therapies (range, 1-3) were treated. The tucatinib maximum tolerated dosage was determined to be 300 mg administered twice per day with dose-limiting toxic reactions seen at 350 mg twice per day. Pharmacokinetic analysis showed that there was no drug-drug interaction with T-DM1. Adverse events seen among the 50 patients treated at the maximum tolerated dosage regardless of causality included nausea (36 patients; 72%), diarrhea (30 patients; 60%), fatigue (28 patients; 56%), epistaxis (22 patients; 44%), headache (22 patients; 44%), vomiting (21 patients; 42%), constipation (21 patients; 42%), and decreased appetite (20 patients; 40%); the majority of adverse events were grade 1 or 2. Tucatinib-related toxic reactions that were grade 3 and above included thrombocytopenia (7 patients; 14%) and hepatic transaminitis (6 patients; 12%). CONCLUSIONS AND RELEVANCE: In this study, tucatinib in combination with T-DM1 appeared to have acceptable toxicity and to show preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01983501.
引用
- Borges VF, Ferrario C, Aucoin N, et al. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018. PMID: 29955792. doi:10.1001/jamaoncol.2018.1812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。